|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristics** | | **eGFR <30**  **(n = 175)** | **eGFR >30-59**  **(n = 175)** | **P-value** |
| **Mean age- years + SD** | | 75.81 ± 11.15 | 75.84 ± 8.81 | 0.9746 |
| **Male sex- n(%)** | | 98 (56.0) | 109 (62.3) | 0.2769 |
| **Race- n(%)** | Caucasian/White | 117 (66.9) | 136 (77.7) | 0.0316 |
| Black | 30 (17.2) | 18 (10.3) | 0.0874 |
| Asian | 3 (1.7) | 5 (2.9) | 0.7206 |
| Other | 25 (14.3) | 16 (9.1) | 0.1305 |
| **Type of ASCVD- n(%)** | Cerebrovascular | 5 (2.9) | 1 (0.58) | 0.2167 |
| Peripheral | 2 (1.2) | 1 (0.58) | 1.0000 |
| Cardiovascular | 111 (63.4) | 112 (64.0) | 1.0000 |
| Multiple | 57 (32.6) | 61 (34.9) | 0.7345 |
| **Additional risk factors- n(%)** | Diabetes | 115 (65.7) | 77 (44.0) | <0.0001 |
| Hypertension | 163 (93.2) | 154 (88.0) | 0.1434 |
| Heart Failure | 87 (49.7) | 60 (34.2) | 0.0049 |
| **Mean SBP - mmHg + SD** | | 134.06 + 19.94 | 127.95 + 18.82 | 0.0035 |
| **Mean DBP - mmHg + SD** | | 71.47 ± 11.29 | 71.01 ± 10.79 | 0.6952 |
| **Smoking status- n(%)** | Past Smoker | 93 (53.2) | 89 (50.9) | 0.7482 |
| Never Smoker | 69 (39.4) | 72 (41.2) | 0.8275 |
| Current Smoker | 13 (7.4) | 14 (8.0) | 1.0000 |
| **Statin therapy- n(%)** | Atorvastatin | 112 (64.0) | 104 (59.4) | 0.3797 |
| Rosuvastatin | 37 (21.2) | 46 (26.3) | 0.2587 |
| Pravastatin | 6 (3.4) | 6 (3.4) | 1.0000 |
| Simvastatin | 15 (8.6) | 17 (9.7) | 0.7111 |
| Pitavastatin | 1 (0.58) | 1 (0.58) | 1.0000 |
| Lovastatin | 4 (2.3) | 1 (0.58) | 0.1772 |
| **Mean eGFR - mL/min/1.73m2 + SD**  *ASCVD; atherosclerotic cardiovascular disease; eGFR; estimated glomerular filtration rate; DBP; diastolic blood pressure; LDL; low-density lipoprotein; n; number of subjects SBP; systolic blood pressure; SD; standard deviation* | | 22.11 ± 6.06 | 47.12 ± 8.15 | 0.0001 |

**Supplementary Appendix: Baseline Characteristics**